Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005

Journal of Cystic Fibrosis

Volumn 8, Issue 6, 2009, Pages 386-391

  Millar, F A ^a   Simmonds, N J ^a   Hodson, M E ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Colonisation; Cystic fibrosis; Pathogens; Sputum

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEPHALOSPORIN; METICILLIN; PENICILLIN G;

ADOLESCENT; ADULT; ARTICLE; ASPERGILLUS; BACTERIAL COLONIZATION; BURKHOLDERIA CEPACIA; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; PREVALENCE; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HUMANS; MALE; PNEUMONIA; PREVALENCE; PULMONARY ASPERGILLOSIS; RETROSPECTIVE STUDIES; SPUTUM; YOUNG ADULT;

EID: 70449674486     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2009.08.003     Document Type: Article

References (25)

1. Davis P.B. Cystic Fibrosis. Pediatr Rev 22 (2001) 257-264
2. Elston C., Simmonds N., and Geddes D. The future for a child born with cystic fibrosis today. Breathe 4 (2007) 17
3. Smyth A. Update on treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 12 (2006) 440-444
4. Corey M., and Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 143 (1996) 1007-1017
5. Ratjen F. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Int J Antimicrob Agents 17 (2001) 93-96
6. Levy J. Antibiotic therapy in cystic fibrosis. Evaluation of efficacy. Chest 94 (1988) 150S-156S
7. Rubin B.K. Emerging therapies for cystic fibrosis lung disease. Chest 115 (1999) 1120-1126
8. Mearns M.B., Hunt G.H., and Rushworth R. Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71. Arch Dis Child 47 (1972) 902-907
9. Littlewood J.M., Miller M.G., Ghoneim A.T., and Ramsden C.H. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet i (1985) 865
10. Frederiksen B., Lanng S., Koch C., and Hoiby N. Improved survival in the Danish centre-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 21 (1996) 153-158
11. Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 49 (1994) 531-532
12. Southern K.W., and Barker P.M. Azithromycin for cystic fibrosis. Eur Respir J 24 (2004) 834-838
13. Burns J.L., Van Dalfsen J.M., Shawar R.M., Otto K.L., Garber R.L., Quan J.M., et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179 (1999) 1190-1196
14. Beringer P.M., and Appleman M.D. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features. Curr Opin Pulm Med 6 (2000) 545-550
15. Isles A., Maclusky I., Corey M., Gold R., Prober C., Fleming P., et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 104 (1984) 206-210
16. Yankaskas J.R., Marshall B.C., Sufian B., Simon R.H., and Rodman D. Cystic fibrosis adult care: consensus conference report. Chest 125 1 Suppl (2004) 1S-39S
17. Burns J.L., Emerson J., Stapp J.R., Yim D.L., Krzewinski J., Louden L., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 27 (1998) 158-163
18. Rodman D.M., Polis J.M., Heltshe S.L., Sontag M.K., Chacon C., Rodman R.V., et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 171 (2005) 621-626
19. Cystic Fibrosis Foundation. Patient Registry Annual Data Report (2005)
20. Accurso F.J. Update in cystic fibrosis 2005. Am J Respir Crit Care Med 173 (2006) 944-947
21. Canton R., Cobos N., de Gracia J., Baquero F., Honorato J., Gartner S., et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 11 (2005) 690-703
22. Ramsey B.W., Dorkin H.L., Eisenberg J.D., et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 328 (1993) 1740-1746
23. Hodson M.E., Gallagher C.G., and Govan J.R. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 20 (2002) 658-664
24. Kerem E., Reisman J., Corey M., Canny G.J., and Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326 (1992) 1187-1191
25. Elborn J.S., and Bell S.C. Nutrition and survival in cystic fibrosis. Thorax 51 (1996) 971-972